TY - JOUR
T1 - Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-Activated receptor α and fundamentally changing lipid metabolism
AU - Cao, Duoyao
AU - Khan, Zakir
AU - Li, Xiaomo
AU - Saito, Suguru
AU - Bernstein, Ellen A.
AU - Victor, Aaron R.
AU - Ahmed, Faizan
AU - Hoshi, Aoi O.
AU - Veiras, Luciana C.
AU - Shibata, Tomohiro
AU - Che, Mingtian
AU - Cai, Lei
AU - Temel, Ryan E.
AU - Giani, Jorge F.
AU - Luthringer, Daniel J.
AU - Divakaruni, Ajit S.
AU - Okwan-Duodu, Derick
AU - Bernstein, Kenneth E.
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
PY - 2023/7
Y1 - 2023/7
N2 - Aims: The metabolic failure of macrophages to adequately process lipid is central to the aetiology of atherosclerosis. Here, we examine the role of macrophage angiotensin-converting enzyme (ACE) in a mouse model of PCSK9-induced atherosclerosis. Methods and results: Atherosclerosis in mice was induced with AAV-PCSK9 and a high-fat diet. Animals with increased macrophage ACE (ACE 10/10 mice) have a marked reduction in atherosclerosis vs. WT mice. Macrophages from both the aorta and peritoneum of ACE 10/10 express increased PPARα and have a profoundly altered phenotype to process lipids characterized by higher levels of the surface scavenger receptor CD36, increased uptake of lipid, increased capacity to transport long chain fatty acids into mitochondria, higher oxidative metabolism and lipid β-oxidation as determined using 13C isotope tracing, increased cell ATP, increased capacity for efferocytosis, increased concentrations of the lipid transporters ABCA1 and ABCG1, and increased cholesterol efflux. These effects are mostly independent of angiotensin II. Human THP-1 cells, when modified to express more ACE, increase expression of PPARα, increase cell ATP and acetyl-CoA, and increase cell efferocytosis. Conclusion: Increased macrophage ACE expression enhances macrophage lipid metabolism, cholesterol efflux, efferocytosis, and it reduces atherosclerosis. This has implications for the treatment of cardiovascular disease with angiotensin II receptor antagonists vs. ACE inhibitors.
AB - Aims: The metabolic failure of macrophages to adequately process lipid is central to the aetiology of atherosclerosis. Here, we examine the role of macrophage angiotensin-converting enzyme (ACE) in a mouse model of PCSK9-induced atherosclerosis. Methods and results: Atherosclerosis in mice was induced with AAV-PCSK9 and a high-fat diet. Animals with increased macrophage ACE (ACE 10/10 mice) have a marked reduction in atherosclerosis vs. WT mice. Macrophages from both the aorta and peritoneum of ACE 10/10 express increased PPARα and have a profoundly altered phenotype to process lipids characterized by higher levels of the surface scavenger receptor CD36, increased uptake of lipid, increased capacity to transport long chain fatty acids into mitochondria, higher oxidative metabolism and lipid β-oxidation as determined using 13C isotope tracing, increased cell ATP, increased capacity for efferocytosis, increased concentrations of the lipid transporters ABCA1 and ABCG1, and increased cholesterol efflux. These effects are mostly independent of angiotensin II. Human THP-1 cells, when modified to express more ACE, increase expression of PPARα, increase cell ATP and acetyl-CoA, and increase cell efferocytosis. Conclusion: Increased macrophage ACE expression enhances macrophage lipid metabolism, cholesterol efflux, efferocytosis, and it reduces atherosclerosis. This has implications for the treatment of cardiovascular disease with angiotensin II receptor antagonists vs. ACE inhibitors.
KW - PPARα
KW - angiotensin converting enzyme
KW - atherosclerosis
KW - lipid metabolism
KW - macrophages
UR - http://www.scopus.com/inward/record.url?scp=85164512753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164512753&partnerID=8YFLogxK
U2 - 10.1093/cvr/cvad082
DO - 10.1093/cvr/cvad082
M3 - Article
C2 - 37225143
AN - SCOPUS:85164512753
SN - 0008-6363
VL - 119
SP - 1825
EP - 1841
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 9
ER -